Literature DB >> 16362855

Fractional flow reserve assessment to determine the indications for myocardial revascularisation in patients with borderline stenosis of the left main coronary artery.

Jacek Legutko1, Dariusz Dudek, Lukasz Rzeszutko, Marcin Wizimirski, Jacek S Dubiel.   

Abstract

INTRODUCTION: Reliable assessment of clinical significance of borderline angiographic lesions found within the left main coronary artery (LM) is often impossible. Measurement of fractional flow reserve (FFR) is commonly used to verify borderline stenoses of the coronary arteries. However, the usefulness of FFR measurements has been validated only for arteries other than the LM. AIM: Evaluation of the measured FFR value in determination of the indications for myocardial revascularisation in borderline LM stenosis.
METHODS: The study involved 38 patients aged 55+/-9 years (range 41-74 years) with isolated borderline LM stenosis. Each patient had the measurement of FFR performed during intravenous adenosine infusion at a dose of 140 microg/kg/min. Patients were referred for revascularisation if FFR was <0.75.
RESULTS: The mean LM stenosis in quantitative coronary angiography (QCA) was 45+/-10%. FFR<0.75 was found in 18 (47%) patients, whereas 20 (53%) subjects had FFR < or =0.75. In subjects with FFR <0.75 QCA showed significantly lower minimal lumen diameters (MLD) at the site of stenosis (1.84+/-0.45 vs 2.24+/-0.49, p=0.014). Additionally, a significant correlation was found between FFR and MLD (r=0.59, p<0.001). The mean clinical follow-up was 2 years (range 1-3 years). There were two (11%) fatal events in patients with FFR < or =0.75 who underwent CABG. One (5%) patient with FFR >0.75 underwent elective CABG due to progression of LMN stenosis. Moreover, one (5%) patient experienced myocardial infarction not related to borderline stenosis of the LM.
CONCLUSIONS: The measurement of FFR confirms the clinical significance of stenosis only in half of the patients with borderline isolated lesion of the left main coronary artery. Withdrawal from intervention in patients with FFR > or =0.75 is safe and is associated with favourable clinical outcomes in two-year follow-up.

Entities:  

Mesh:

Year:  2005        PMID: 16362855

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  7 in total

1.  Use of fractional flow reserve and intravascular ultrasonography to evaluate ambiguous left main coronary artery stenosis.

Authors:  Harvinder Arora; William Posligua; Andrés Mesa
Journal:  Tex Heart Inst J       Date:  2008

Review 2.  Current Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Intervention.

Authors:  Harsha S Nagarajarao; Chandra P Ojha; Venkatachalam Mulukutla; Ahmed Ibrahim; Adriana C Mares; Timir K Paul
Journal:  Curr Cardiol Rep       Date:  2020-02-08       Impact factor: 2.931

3.  Fractional flow reserve application in everyday practice: adherence to clinical recommendations.

Authors:  Katia Orvin; Tamir Bental; Alon Eisen; Hana Vaknin-Assa; Abid Assali; Eli I Lev; David Brosh; Ran Kornowski
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

Review 4.  Clinical Relevance of Coronary Fractional Flow Reserve: Art-of-state.

Authors:  Yohanes Adiputra; Shao-Liang Chen
Journal:  Chin Med J (Engl)       Date:  2015-05-20       Impact factor: 2.628

5.  Invasive and non-invasive fractional flow reserve index in validation of hemodynamic severity of intracoronary lesions.

Authors:  Jarosław Wasilewski; Kryspin Mirota; Michał Hawranek; Lech Poloński
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-06-17       Impact factor: 1.426

6.  The role of FFR in clinical decision making in patients with moderate coronary lesions: a pilot study.

Authors:  Morteza Safi; Mohammad Ali Mehrabi; Saeed Alipour Parsa; Isa Khaheshi; Mohammadreza Naderian
Journal:  Acta Biomed       Date:  2018-10-08

Review 7.  Physiology-Based Revascularization of Left Main Coronary Artery Disease.

Authors:  Peter Kayaert; Mathieu Coeman; Sofie Gevaert; Michel De Pauw; Steven Haine
Journal:  J Interv Cardiol       Date:  2021-02-10       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.